Global Fund Eligibility List 2020

The Global Fund has updated its Eligibility List for 2020. This updated list is based on the same eligibility criteria:

  • Income classification (based on updated 2019 World Bank classifications through the Atlas Method) with classifications Low Income Countries (LICs), Lower-Middle Income Countries (LMICs), and UpperMiddle Income Countries (UMICs)
  • Disease Burden based on WHO and UNAIDS indicators. This criterion is only applicable to Upper Middle-Incomes to determine their eligibility since all low and lower-middle income countries are eligible for funding.
  • Transition Funding (wherein one additional allocation period following the change of eligibility will be taken into consideration for existing grants)

Twenty eight (28) Asia and the Pacific countries are eligible for funding under the 2020-2022 Funding Cycle. These are Afghanistan, Bangladesh, Bhutan, Cambodia,  India, Indonesia, Kiribati (except for malaria), DPR Korea, Malaysia (except for malaria), Maldives (except for malaria), Marshall Islands (except for malaria), Mongolia (except for malaria), Myanmar, Nauru (only for TB), Nepal, Pakistan, Papua New Guinea, Philippines, Russian Federation (only for HIV), Samoa (except for malaria), Solomon Islands, Sri Lanka (except for malaria), Thailand, Timor Leste, Tonga (except for malaria), Tuvalu (except for malaria), Vanuatu, and Viet Nam.

Fiji became ineligible despite its high TB disease burden due to its non-eligibility in other diseases since 2019. Nauru, on the other hand, became eligible for TB despite its re-classification to an Upper Middle-Income (UMI). This, however, does not confirm budget allocation. Russian Federation has been granted eligibility under HIV but only for civil society organizations and key population networks working on the HIV response. Similar to Nauru, this does not guarantee actual allocation.

Multi-country applications are also only eligible for funding when majority or 51% of countries within the application are eligible for funding for a similar disease through single-country applications.


For more information, visit The Global Fund website.